SCHEMBL2117835

SCHEMBL2117835

COc1ccc(S(=O)(=O)Nc2cc(-c3ccc(C#N)s3)ccc2C)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
PIK3CA P42336 3/20 0.39
MTOR P42345 3/20 0.39
AKT1 P31749 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
STAT3 P40763 2/20 0.37
KEAP1 Q14145 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
PRF1 P14222 1/20 0.36
PIK3CG P48736 1/20 0.36
NAAA Q02083 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117419 0.88 USP2 (0.42) MAPTPIK3CAMTORAKT1ALDH1A1
SCHEMBL2119262 0.86 MAPT (0.37) MAPTPIK3CAMTORAKT1ALDH1A1
SCHEMBL2119515 0.83 CCR9 (0.40) MAPTPIK3CAMTORAKT1ALDH1A1
SCHEMBL2119029 0.83 ACLY (0.49) MAPTPIK3CAMTORALDH1A1CYP2C9
SCHEMBL2119688 0.82 PRF1 (0.47) MAPTALDH1A1PRF1
SCHEMBL2117776 0.81 ACLY (0.38) MAPTALDH1A1HSD17B1HSD17B2PGR
SCHEMBL2118512 0.80 GHSR (0.45) MAPTPIK3CAALDH1A1CYP2C9TSHR
SCHEMBL2117520 0.80 MAPT (0.39) MAPTPIK3CAMTORAKT1ALDH1A1
SCHEMBL2117210 0.80 MAPT (0.42) MAPTPIK3CAMTORALDH1A1CYP2C9
SCHEMBL2118049 0.80 ALDH1A1 (0.40) MAPTPIK3CAMTORALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885PIK3CA 712/4885MTOR 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.